Q32 BIO Aktie

 

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

-- Dr. Sipos is an immunologist and seasoned Immunology and Inflammation (I&I) drug developer, with over 25 years of clinical development and medical affairs leadership experience -- WALTHAM, Mass., June 25, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage......

-- SIGNAL-AA Part B topline data readout on-track for 1H'26 -- WALTHAM, Mass., April 16, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio" or the "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other......

Q32 Bio (QTTB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy)....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

-- Presented bempikibart SIGNAL-AA Phase 2a Part A alopecia areata (AA) data demonstrating encouraging clinical activity and highlighting the potential to be a differentiated treatment as a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting --......

-- Results presented in AAD late-breaker demonstrate bempikibart's encouraging improvement on SALT reduction at week 24 and continued effects after dosing cessation in patients with severe and very severe alopecia areata (AA) -- -- Durable, ongoing responses in multiple patients through......

WALTHAM, Mass., Feb. 26, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in two upcoming investor conferences in......

Q32 Bio (QTTB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

BUZZ-Guggenheim downgrades Q32 Bio to 'neutral' as dermatitis drug fails in part of study ** Guggenheim downgrades drug developer Q32 Bio QTTB.O to "neutral" from "buy" ** Brokerage removes PT; previous PT was $100 ** Co's experimental drug, bempikibart, failed to meet main goal in part of mid-stage trial studying it in patients with atopic dermati...

Shares of QTTB fall after its experimental autoimmune disease drug failed to meet the primary endpoint in a mid-stage study for eczema....

BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 07.35 A.M. ET).In the Green SEALSQ Corp (LAES) is up over 83% at $1.05. CleanCore......

BUZZ-Q32 Bio plummets as dermatitis drug fails in part of a study ** Shares of drug developer Q32 Bio QTTB.O fall 67.64% to $7.90 after market ** QTTB says its experimental drug bempikibart failed to meet the main goal in a part of a mid-stage trial studying it in patients with atopic dermatitis ** The two-part trial was evaluating the drug in adul...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

-- Bempikibart Phase 2 topline results in atopic dermatitis (AD) and alopecia areata (AA) remain on-track for Q4'24, with topline data from both trials expected in December -- -- Enrollment ongoing in ADX-097 Phase 2 basket trial for complement mediated renal diseases, with topline data......

The consensus price target hints at a 91.7% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term....

Q32 Bio Inc reports results for the quarter ended in June - Earnings Summary...

-- Completed enrollment in bempikibart atopic dermatitis (AD) Phase 2 clinical trial and increased trial size to 121 patients based on Part B patient demand -- -- Bempikibart Phase 2 topline results in AD and alopecia areata (AA) remain on-track for Q4'24 -- -- Enrolling patients in the......

FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN Q32 BIO INC. O.N. DB0 US7469641051 AB/FROM ONWARDS 09.07.2024 09:12 CET...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...